SG11201900200XA - Tgfb antibodies, methods, and uses - Google Patents
Tgfb antibodies, methods, and usesInfo
- Publication number
- SG11201900200XA SG11201900200XA SG11201900200XA SG11201900200XA SG11201900200XA SG 11201900200X A SG11201900200X A SG 11201900200XA SG 11201900200X A SG11201900200X A SG 11201900200XA SG 11201900200X A SG11201900200X A SG 11201900200XA SG 11201900200X A SG11201900200X A SG 11201900200XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- protgfb1
- massachusetts
- johnson
- rule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 3E1 0 01111110111 00111111 001110 11110 IIE OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/013939 Al 18 January 2018 (18.01.2018) W I P0 I P C T (51) International Patent Classification: (US). TURNER, Katherine; 4 Hazelnut Street, Acton, A61K 38/18 (2006.01) C07K 16/22 (2006.01) Massachusetts 01720 (US). A61K 39/00 (2006.01) C07K 16/28 (2006.01) A61K 39/395 (2006.01) Cl 2N 9/00 (2006.01) (74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New (21) International Application Number: Brunswick, New Jersey 08933 (US). PCT/US2017/042162 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 14 July 2017 (14.07.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (30) Priority Data: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/362,393 14 July 2016 (14.07.2016) US August 2016 (05.08.2016) US 62/371,355 05 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: SCHOLAR ROCK, INC. [US/US]; 620 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Memorial Drive, Cambridge, Massachusetts 02139 (US). (84) Designated States (unless otherwise indicated, for every (72) Inventors: CARVEN, Gregory J.; 89 Brooks Street, May- kind of regional protection available): ARIPO (BW, GH, — nard, Massachusetts 01754 (US). SCHURPF, Thomas; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 620 Memorial Drive, Cambridge, Massachusetts 02139 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = = (54) Title: TGFB ANTIBODIES, METHODS, AND USES = = = Figure 1 = = = Teri Teff Treg = = — = = = = :I 'S * .; . @cm 213-1C1 IM 43-1669 I = e _ ug/mL = * p < 9 01 when compared to IgG con i 1 - using Durtnette 1-way ANOVA 11 C:r M C:r M 1-1 (57) : ProTGFB1-GARP complex-selective antibodies, polynucleotides capable of encoding the proTGFB1-GARP com- = - plex-selective antibodies or antigen-binding fragments, cells expressing proTGFB1-GARP complex-selective antibodies or anti- GC gen-binding fragments, as well as associated vectors and detectably labeled proTGFB1-GARP complex-selective antibodies or anti- 1-1 © gen-binding fragments may be used to enhance an immune response in a subject, for example, against a cancer. ei o [Continued on next page] WO 2018/013939 Al MIDEDIMOMOIDEIREEMOOMMOIIIMMIIMIDEVOIS TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662362393P | 2016-07-14 | 2016-07-14 | |
US201662371355P | 2016-08-05 | 2016-08-05 | |
PCT/US2017/042162 WO2018013939A1 (en) | 2016-07-14 | 2017-07-14 | Tgfb antibodies, methods, and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900200XA true SG11201900200XA (en) | 2019-02-27 |
Family
ID=60953402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900200XA SG11201900200XA (en) | 2016-07-14 | 2017-07-14 | Tgfb antibodies, methods, and uses |
Country Status (13)
Country | Link |
---|---|
US (2) | US20190292254A1 (en) |
EP (1) | EP3484499A4 (en) |
JP (2) | JP7128801B2 (en) |
KR (1) | KR102577551B1 (en) |
CN (1) | CN110049773A (en) |
AU (1) | AU2017294772B2 (en) |
BR (1) | BR112019000621A2 (en) |
CA (1) | CA3030862A1 (en) |
IL (1) | IL264161A (en) |
MA (1) | MA45690A (en) |
MX (1) | MX2019000514A (en) |
SG (1) | SG11201900200XA (en) |
WO (1) | WO2018013939A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105658666B (en) | 2013-08-01 | 2021-07-27 | 鲁汶大学 | anti-GARP protein and application thereof |
SG11201807176XA (en) | 2016-03-11 | 2018-09-27 | Scholar Rock Inc | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF |
GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
EP3820896A1 (en) * | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | TGFbeta1 INHIBITORS AND USE THEREOF |
SI3677278T1 (en) | 2018-07-11 | 2022-01-31 | Scholar Rock, Inc. | Isoform selective tgfbeta1 inhibitors and use thereof |
EP3863722A2 (en) | 2018-10-10 | 2021-08-18 | Tilos Theapeutics, Inc. | Anti-lap antibody variants and uses thereof |
WO2020160291A2 (en) | 2019-01-30 | 2020-08-06 | Scholar Rock, Inc. | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
CN114630679A (en) * | 2019-10-25 | 2022-06-14 | 第一三共株式会社 | Combination of anti-GARP antibodies and immunomodulators |
US10822379B1 (en) * | 2020-03-12 | 2020-11-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Molecules that bind to SARS-CoV-2 |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
CA3230246A1 (en) * | 2021-09-30 | 2023-04-06 | Wenxin Xu | Bispecific antibody and use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2284194A1 (en) * | 2004-12-21 | 2011-02-16 | AstraZeneca AB | Antibodies directed to angiopoietin-2 and uses thereof |
RU2478709C2 (en) * | 2005-07-21 | 2013-04-10 | Эбботт Лэборетриз | GENE SET EXPRESSION INCLUDING sORF CONSTRUCTS AND METHODS FOR IMMUNOGLOBULIN EXPRESSION |
US7767206B2 (en) * | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
EP2573175B1 (en) * | 2010-05-18 | 2020-07-08 | Medical and Biological Laboratories Co., Ltd. | ANTIBODY CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING ANTIPROLIFERATIVE ACTIVITY ON CANCER HAVING Ras GENE MUTATION |
SI2904011T1 (en) * | 2012-10-02 | 2017-10-30 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
CA2911514A1 (en) * | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
CN105658666B (en) | 2013-08-01 | 2021-07-27 | 鲁汶大学 | anti-GARP protein and application thereof |
EP3139957A4 (en) * | 2014-05-06 | 2018-04-25 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
US11597778B2 (en) * | 2015-04-07 | 2023-03-07 | The Trustees Of The University Of Pennsylvania | Human monoclonal autoantibodies to ADAMTS13 and uses thereof |
TWI717375B (en) * | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
-
2017
- 2017-07-14 SG SG11201900200XA patent/SG11201900200XA/en unknown
- 2017-07-14 MX MX2019000514A patent/MX2019000514A/en unknown
- 2017-07-14 EP EP17828542.5A patent/EP3484499A4/en active Pending
- 2017-07-14 MA MA045690A patent/MA45690A/en unknown
- 2017-07-14 AU AU2017294772A patent/AU2017294772B2/en active Active
- 2017-07-14 KR KR1020197004053A patent/KR102577551B1/en active IP Right Grant
- 2017-07-14 US US16/317,635 patent/US20190292254A1/en not_active Abandoned
- 2017-07-14 WO PCT/US2017/042162 patent/WO2018013939A1/en unknown
- 2017-07-14 CA CA3030862A patent/CA3030862A1/en active Pending
- 2017-07-14 JP JP2019501541A patent/JP7128801B2/en active Active
- 2017-07-14 BR BR112019000621-4A patent/BR112019000621A2/en unknown
- 2017-07-14 CN CN201780056570.4A patent/CN110049773A/en active Pending
-
2019
- 2019-01-09 IL IL264161A patent/IL264161A/en unknown
-
2021
- 2021-05-25 US US17/329,859 patent/US20210277100A1/en active Pending
-
2022
- 2022-07-05 JP JP2022108096A patent/JP2022153406A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017294772B2 (en) | 2024-05-02 |
AU2017294772A1 (en) | 2019-01-31 |
US20210277100A1 (en) | 2021-09-09 |
JP2019524094A (en) | 2019-09-05 |
EP3484499A1 (en) | 2019-05-22 |
JP2022153406A (en) | 2022-10-12 |
MA45690A (en) | 2019-05-22 |
KR102577551B1 (en) | 2023-09-11 |
IL264161A (en) | 2019-02-28 |
KR20190034560A (en) | 2019-04-02 |
CN110049773A (en) | 2019-07-23 |
MX2019000514A (en) | 2019-07-12 |
WO2018013939A1 (en) | 2018-01-18 |
EP3484499A4 (en) | 2020-05-13 |
US20190292254A1 (en) | 2019-09-26 |
BR112019000621A2 (en) | 2019-04-24 |
CA3030862A1 (en) | 2018-01-18 |
JP7128801B2 (en) | 2022-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900200XA (en) | Tgfb antibodies, methods, and uses | |
SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201901210UA (en) | Ferroelectric memory cells | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201806650VA (en) | Systems and methods for providing a personal distributed ledger | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201908131RA (en) | Benzazepine compounds, conjugates, and uses thereof | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201900269XA (en) | Channel sensing for independent links | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201907820SA (en) | Inhibitors of (alpha-v)(beta-6) integrin | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201809522WA (en) | Method of nucleic acid sequence determination | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201901168UA (en) | Apparatuses and methods including ferroelectric memory and for operating ferroelectric memory | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 |